SCHEMBL19810310

SCHEMBL19810310

O=c1c(Cc2ccco2)nc2c(Cc3ccccc3)[nH]c(-c3ccc(-c4ccccc4)cc3)cn1-2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2B P29275 9/20 0.38
▸ ADORA2A P29274 8/20 0.38
▸ ALDH1A1 P00352 6/20 0.38
▸ TSHR P16473 4/20 0.38
▸ BRD4 O60885 1/20 0.35
▸ HSD17B10 Q99714 4/20 0.35
▸ ALOX15 P16050 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ ALKBH3 Q96Q83 1/20 0.35
▸ CASP1 P29466 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ USP2 O75604 2/20 0.34
▸ POLB P06746 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ BLM P54132 2/20 0.34
▸ CASP7 P55210 2/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2670126 0.98 ALDH1A1 (0.39) ADORA2BADORA2AALDH1A1TSHRBRD4
SCHEMBL28888591 0.93 PSD (0.38) ADORA2BADORA2AALDH1A1TSHRHSD17B10
SCHEMBL19810320 0.93 LTB4R (0.36) ADORA2BADORA2AALDH1A1TSHRHSD17B10
SCHEMBL19810212 0.93 ALDH1A1 (0.38) ADORA2BADORA2AALDH1A1TSHRHSD17B10
SCHEMBL5560844 0.93 ALDH1A1 (0.37) ADORA2BADORA2AALDH1A1TSHRHSD17B10
SCHEMBL28391210 0.93 PRNP (0.36) ADORA2BADORA2AALDH1A1TSHRHSD17B10
SCHEMBL28394541 0.92 ADORA2B (0.35) ADORA2BADORA2AALDH1A1TSHRBRD4
SCHEMBL25781925 0.92 ADORA2B (0.35) ADORA2BADORA2AALDH1A1TSHRBRD4
SCHEMBL20211769 0.92 TSHR (0.36) ADORA2BADORA2AALDH1A1TSHRHSD17B10
SCHEMBL19810309 0.91 MEN1 (0.37) ADORA2BADORA2AALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10669280-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2020-06-02 — — US claimed
EP-3490991-A1 COELENTERAZINE ANALOGUES Promega Corporation (US) 2019-06-05 — — EP claimed
US-10000500-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2018-06-19 — — US claimed
WO-2018022865-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2018-02-01 — — WO claimed
US-20180030059-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-02-01 — — US claimed
EP-3490991-B1 COELENTERAZINE ANALOGUES PROMEGA CORP (US) 2021-01-06 — — EP disclosed
EP-3490991-B1 COELENTERAZINE ANALOGUES PROMEGA CORP (US) 2021-01-06 — — EP disclosed
US-10669280-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2020-06-02 — — US disclosed
US-10669280-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2020-06-02 — — US disclosed
US-10428075-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2019-10-01 — — US disclosed
US-10428075-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2019-10-01 — — US disclosed
EP-3490991-A1 COELENTERAZINE ANALOGUES Promega Corporation (US) 2019-06-05 — — EP disclosed
US-20180334463-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-11-22 — — US disclosed
US-10000500-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2018-06-19 — — US disclosed
US-10000500-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2018-06-19 — — US disclosed
US-10000500-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2018-06-19 — — US disclosed
WO-2018022865-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2018-02-01 — — WO disclosed
US-20180030059-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-02-01 — — US disclosed
US-20180030059-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-02-01 — — US disclosed
US-20180030059-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000500-B2 Coelenterazine analogues GLB1, TCF7L2, SI ADORA2B 3223/4885ADORA2A 2012/4885ALDH1A1 3416/4885
US-10669280-B2 Coelenterazine analogues GLB1, SI, TCF7L2 ADORA2B 3105/4885ADORA2A 1970/4885ALDH1A1 3541/4885
US-10428075-B2 Coelenterazine analogues GLB1, SI, TCF7L2 ADORA2B 3105/4885ADORA2A 1970/4885ALDH1A1 3541/4885
US-20180030059-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 ADORA2B 3105/4885ADORA2A 1970/4885ALDH1A1 3541/4885
US-20180334463-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 ADORA2B 3105/4885ADORA2A 1970/4885ALDH1A1 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback